The
global Hearing Loss Disease Treatment Market size is
expected to reach USD 19.36 billion by 2030, registering a CAGR of 5.25% from
2024 to 2030, according to a new report by Grand View Research, Inc. The
growth is attributed to the global rise in disease burden, initiatives
undertaken by government and private organizations to spread awareness among
people, and the growing geriatric population in the world. Furthermore, the
increasing number of clinical pipeline drugs and advancements with auditory
devices offer lucrative opportunities for industry growth. The world is
witnessing an increasing prevalence of hearing loss cases, which is the key
factor driving the industry's growth.
For
instance, according to the WHO reports, in 2021, over 5% of the world’s
population, or around 430 million people, require rehabilitation to manage
their listening disability. Moreover, by 2050, nearly 2.5 billion people are
estimated to be impacted by listening impairment across the globe. As per the
report, low- and middle-income countries account for 80% of people suffering
from a disability. Aging has further led to an increase in the prevalence of
the disease. Globally, approximately 25% of people aged 60 years are affected
by hearing loss. Therefore, the rising disease cases increase the demand for
treatment and drive the space. The space has the presence of a robust clinical
trial pipeline, which is expected to offer better treatment options in the
coming years.
This
can be anticipated due to the presence of more than 45 therapies at different
phases of clinical investigation. For instance, Sound Pharmaceuticals’ Ebselen
and Sensorion’s SENS-401 are under phase 3 clinical studies indicated for the
treatment of Meniere’s Disease and sensorineural hearing loss, respectively.
Similarly, in June 2022, Pipeline Therapeutics’ phase 2 drug, PIPE-505 is being
evaluated for sensorineural hearing loss. Therefore, the launch of new
treatment options in the coming years is expected to offer a lucrative
opportunity for the industry. Rising technological advancements, such as
AI-associated innovations, in auditory products, are boosting the industry.
The
launch of products with advanced features like operating through smartphones
and rechargeable & waterproof devices is enhancing customer experience. For
instance, in June 2022, GN Hearing launched Custom made by Resound, a
chargeable hearing aid that supports wireless streaming from Android and iOS.
Key players are implementing strategic initiatives, such as new launches,
collaborations, agreements, and financial investments, which are further
driving the industry. For instance, in April 2022, Autigen entered into a
collaboration and licensing agreement with Boehringer Ingelheim to develop
advanced therapies for people suffering from sensorineural conditions.
Similarly, in September 2022, Fennec Pharmaceuticals announced the FDA approval
for Pedmarkto prevents hearing loss in pediatric patients going through
chemotherapy.
List
of Key Players of Hearing Loss Disease Treatment Market
- Novartis AG
- Acousia
Therapeutics GmbH
- Otonomy, Inc.
- Sensorion
- Frequency
Therapeutics
- Audifon GmbH
& Co. KG
- Pipeline
Therapeutics
- Audina
Hearing Instruments, Inc.
- Astellas
Pharma, Inc.
- WS Audiology
A/S
Request a free sample copy or view report
summary: Hearing Loss Disease Treatment Market Report
Hearing
Loss Disease Treatment Market Report Highlights
- The devices
segment dominated the industry in 2023 and accounted for the maximum share
of more than 90.65% of the overall revenue. This can be attributed to
technological advancements in devices, high prevalence coupled with the
rising benefits of devices.
- The drugs
segment is estimated to register the fastest CAGR over the forecast period
due to the launch of new therapeutic products. Drugs are available for
several types of hearing problems.
- The
sensorineural hearing loss segment dominated the industry in 2023 and
accounted for the maximum share of more than 57.04% of the total revenue
and is estimated to be the fastest growing segment over the forecast
period.
- The otology
clinics end-user segment, in 2023, accounted for the second-highest share
of 45.18% of the overall revenue.
- Asia Pacific
is expected to be the fastest-growing region from 2024 to 2030 due to the
rising number of target patients and funding support to major players in
the region.
Hearing
Loss Disease Treatment Market Segmentation
Grand
View Research has segmented the global hearing loss disease treatment market
report on the basis of product, disease type, end-user, and region:
Hearing
Loss Disease Treatment Product Outlook (Revenue, USD Million, 2018 - 2030)
- Devices
- Drugs
- Systemic
steroids
- Antiviral
medication
- Vasodilators
- Others
Hearing
Loss Disease Treatment Disease Type Outlook (Revenue, USD Million, 2018 -
2030)
- Conductive
Hearing Loss
- Sensorineural
Hearing Loss
- Mixed
(Conductive and Sensorineural)
Hearing
Loss Disease Treatment End-user Outlook (Revenue, USD Million, 2018 -
2030)
- Hospitals
- Otology
clinics
- Ambulatory
clinics
Hearing
Loss Disease Treatment Regional Outlook (Revenue, USD Million, 2018 -
2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment